South China Morning Post

Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists are synthetic...

By South China Morning Post

1 min read
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Startups & Entrepreneurship

Related Insights